GlobalData on MSN
FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.
If you collect new sports cards, you've probably seen the same line over and over again when a new set comes out: "This product is available through EQL." Many collectors find that message confusing, ...
B SkyWater Technology (SKYT) deal brings in-house quantum chip manufacturing, speeding iteration and scalability. Read more ...
The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results